التفاصيل البيبلوغرافية
| العنوان: |
The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. |
| المؤلفون: |
Vig, Sierra J.1 sierravig@gmail.com, Garza, Julia2, Tao, Yunting2 |
| المصدر: |
Headache: The Journal of Head & Face Pain. Nov2022, Vol. 62 Issue 10, p1256-1263. 8p. |
| مصطلحات موضوعية: |
*MIGRAINE prevention, *THERAPEUTIC use of monoclonal antibodies, *PREMATURE infants, *MIGRAINE, *MONOCLONAL antibodies, *HUMAN abnormalities, *PREGNANCY outcomes, *NEUROTRANSMITTER receptors, *CHEMICAL inhibitors, *DISEASE risk factors, *PREGNANCY, RISK factors in miscarriages |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Objective: To report a case of a woman who continued erenumab for migraine prophylaxis throughout her pregnancy and to review the literature for pregnancy safety data for the calcitonin gene‐related peptide (CGRP) receptor and ligand‐directed therapies currently approved for migraine prophylaxis in the United States. Background: Migraine is a common headache disorder that can be significantly disabling. Many people experiencing migraine seek out preventative therapies to improve their quality of life. Unfortunately, currently approved prophylactic agents may not be safe to use during pregnancy, potentially limiting the use of these agents in women of childbearing potential. As the newest class of prophylactic agents for migraine, CGRP agents have limited pregnancy safety data in humans. Methods: A review of the literature was conducted through the PubMed database using the terms pregnancy and either erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, or atogepant. Additional sources of information such as prescribing information, assessment reports submitted to the European Medicines Agency (EMA), and manufacturer data were sought. Results: One case report was found in the literature documenting a human pregnancy with no adverse effects in the baby after exposure to erenumab. However, the last dose was administered in the second week of pregnancy and discontinued thereafter. The evaluation of 92 safety reports describing maternal exposure prior to or during pregnancy to either erenumab, galcanezumab, or fremanezumab was located. Incidence of miscarriage and congenital anomalies appear to be similar to rates in the general population. Conclusions: The use of erenumab during pregnancy in our patient resulted in no known harm to the child. This case is unique in that the mother continued to receive erenumab throughout the pregnancy. Safety data is lacking regarding the use of these agents during pregnancy, despite their frequent use in women of childbearing potential. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
